VEOZA

This brand name is authorized in Estonia, France, Croatia, Ireland, Lithuania, United Kingdom

Active ingredients

The drug VEOZA contains one active pharmaceutical ingredient (API):

1 Fezolinetant UNII 83VNE45KXX - FEZOLINETANT

Fezolinetant is a non-hormonal selective neurokinin 3 (NK3) receptor antagonist. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus. Read about Fezolinetant

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VEOZA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G02CX06		G Genito urinary system and sex hormones → G02 Other gynecologicals → G02C Other gynecologicals → G02CX Other gynecologicals
Discover more medicines within G02CX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3056172, 3056183, 3056194
Country: FR	Base de données publique des médicaments	Identifier(s): 66063738
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098569, 1098570, 1098571, 1099529